SUBSCRIBE
SUBSCRIBE
News   Drug Development

U.S. FDA Says Takeda Pharmaceutical Co. Ltd. Sleep Drug Promotion Misleads

March 22, 2010 | 
1 min read

Reuters -- Japan's Takeda Pharmaceutical Co (4502.T) used a misleading promotion for its insomnia drug Rozerem, U.S. regulators said in a letter released on Friday.

Clinical research Postmarket research Regulatory
Takeda Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Handshake of man and robot. Modern technologies. Art collage.
Artificial intelligence
Amid Layoffs, Delays, FDA Turns to AI for Speedy Reviews
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone collage. A hand holds a ringing alarm clock. Time, hurry up. Vector business concepts for graphic and web design, marketing and print materials, social media. Vector illustration
Regulatory
FDA Delays Continue as Regulator Misses Review Date for GSK’s Nucala
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
illustration of the ship in the storm, gigantic waves
Special edition
Deep Dive: Biopharma In Turmoil As Peter Marks Forced Out of FDA
May 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Illustration showing businessman avoiding potholes on way to goal
Job Trends
Job Market Woes: More Funding, Stability Needed for Turnaround
May 8, 2025
 · 
5 min read
 · 
Angela Gabriel